@article{Leong2020247,
title = {Poh-tay-toe, Poh-tah-toe: Autism Diagnosis and Conceptualization},
author = {D Leong and D Hedley and M Uljarević},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078570091&doi=10.1177%2f0883073819887587&partnerID=40&md5=f40e68dc7723d94e6c9dfeb9820558a4},
doi = {10.1177/0883073819887587},
issn = {08830738},
year = {2020},
date = {2020-01-01},
journal = {Journal of Child Neurology},
volume = {35},
number = {3},
pages = {247-248},
publisher = {SAGE Publications Inc.},
note = {cited By 0},
keywords = {Anxiety, Attention Deficit Disorder, Autism, Caregiver, Children, Clinical Article, Clinical Practice, Disruptive Behavior, DSM-5, Follow Up, Human, Learning Disorder, Letter, Mental Health, Mood Disorder, Multidisciplinary Team, Neuropsychiatry, Priority Journal, Unemployment, Workforce},
pubstate = {published},
tppubtype = {article}
}

@article{Liu2019,
title = {Effects of lactobacillus plantarum PS128 on children with autism spectrum disorder in Taiwan: A randomized, double-blind, placebo-controlled trial},
author = {Y -W Liu and M T Liong and Y -C E Chung and H -Y Huang and W -S Peng and Y -F Cheng and Y -S Lin and Y -Y Wu and Y -C Tsai},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064817846&doi=10.3390%2fnu11040820&partnerID=40&md5=ca04462e8710198b821b44f8e73061f3},
doi = {10.3390/nu11040820},
issn = {20726643},
year = {2019},
date = {2019-01-01},
journal = {Nutrients},
volume = {11},
number = {4},
publisher = {MDPI AG},
abstract = {This four-week, randomized, double-blind, placebo-controlled study investigated the effects of Lactobacillus plantarum PS128 (PS128) on boys with autism spectrum disorder (ASD) aged 7-15 in Taiwan. All subjects fulfilled the criteria for ASD diagnosis of DSM-V and the Autism Diagnostic Interview-Revised (ADI-R). Questionnaires used for the primary outcome measure include the Autism Behavior Checklist-Taiwan version (ABC-T), the Social Responsiveness Scale (SRS) and the Child Behavior Checklist (CBCL). The Swanson, Nolan, and Pelham-IV-Taiwan version (SNAP-IV) and the Clinical Global Impression-improvement (CGI-I) were used for the secondary outcome measure. The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of SNAP-IV for younger children (aged 7−12) improved significantly compared with the placebo group. Additionally, several elements were also notably improved in the PS128 group after 28-day consumption of PS128. Further studies are needed to better clarify the effects of PS128 for younger children with ASD on broader symptoms. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.},
note = {cited By 4},
keywords = {Aberrant Behavior Checklist Taiwan version, Adolescent, Age, Age Factors, Aggression, Anxiety, Article, Attention Deficit Disorder, Autism, Autism Behavior Checklist, Autism Diagnostic Interview Revised, Autism Spectrum Disorders, Child Behaviour, Child Behaviour Checklist, Children, Clinical Global Impression Scale, Communication Disorder, Controlled Study, Double Blind Procedure, Double-Blind Method, Female, Generalized Anxiety Disorder, Human, Impulsiveness, Lactobacillus Plantarum, Male, Physiology, Placebo, Placebos, Posttraumatic Stress Disorder, Probiotic Agent, Probiotics, Psychology, Questionnaires, Randomized Controlled Trial, Rating Scale, School Child, Scoring System, Social Behaviour, Social Interactions, Social Problem, Social Responsiveness Scale, Surveys, Swanson Nolan and Pelham IV Assessment, Synaptosomal Associated Protein 23, Taiwan},
pubstate = {published},
tppubtype = {article}
}

@article{Tsuchida2018538,
title = {GRIN2D variants in three cases of developmental and epileptic encephalopathy},
author = {N Tsuchida and K Hamada and M Shiina and M Kato and Y Kobayashi and J Tohyama and K Kimura and K Hoshino and V Ganesan and K W Teik and M Nakashima and S Mitsuhashi and T Mizuguchi and A Takata and N Miyake and H Saitsu and K Ogata and S Miyatake and N Matsumoto},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056487337&doi=10.1111%2fcge.13454&partnerID=40&md5=f0d32670db57261820bc244943cffd62},
doi = {10.1111/cge.13454},
issn = {00099163},
year = {2018},
date = {2018-01-01},
journal = {Clinical Genetics},
volume = {94},
number = {6},
pages = {538-547},
publisher = {Blackwell Publishing Ltd},
abstract = {N-methyl-d-aspartate (NMDA) receptors are glutamate-activated ion channels that are widely distributed in the central nervous system and essential for brain development and function. Dysfunction of NMDA receptors has been associated with various neurodevelopmental disorders. Recently, a de novo recurrent GRIN2D missense variant was found in two unrelated patients with developmental and epileptic encephalopathy. In this study, we identified by whole exome sequencing novel heterozygous GRIN2D missense variants in three unrelated patients with severe developmental delay and intractable epilepsy. All altered residues were highly conserved across vertebrates and among the four GluN2 subunits. Structural consideration indicated that all three variants are probably to impair GluN2D function, either by affecting intersubunit interaction or altering channel gating activity. We assessed the clinical features of our three cases and compared them to those of the two previously reported GRIN2D variant cases, and found that they all show similar clinical features. This study provides further evidence of GRIN2D variants being causal for epilepsy. Genetic diagnosis for GluN2-related disorders may be clinically useful when considering drug therapy targeting NMDA receptors. © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd},
note = {cited By 4},
keywords = {Adolescent, Allele, Amino Acid Sequence, Amino Acid Substitution, Amino Terminal Sequence, Anemia, Antibiotic Agent, Antibiotic Therapy, Article, Atonic Seizure, Attention Deficit Disorder, Autism, Binding Affinity, Brain, Brain Atrophy, Carbamazepine, Case Report, Channel Gating, Chemistry, Children, Clinical Article, Clinical Feature, Clobazam, Clonazepam, Conformational Transition, Continuous Infusion, Contracture, Crystal Structure, Cysteine Ethyl Ester Tc 99m, Developmental Delay, Developmental Disorders, Electroencephalogram, Electroencephalography, Epilepsy, Epileptic Discharge, Ethosuximide, Eye Tracking, Febrile Convulsion, Female, Frontal Lobe Epilepsy, Gene, Gene Frequency, Genetic Variation, Genetics, Genotype, GRIN2D Protein, Heterozygosity, Home Oxygen Therapy, Human, Human Cell, Hydrogen Bond, Intellectual Impairment, Intelligence Quotient, Intractable Epilepsy, Ketamine, Lacosamide, Lamotrigine, Lennox Gastaut Syndrome, Levetiracetam, Magnetoencephalography, Male, Maternal Hypertension, Melatonin, Migraine, Missense Mutation, Molecular Dynamics, Molecular Dynamics Simulation, Mutation, Myoclonus Seizure, N Methyl Dextro Aspartic Acid Receptor, N Methyl Dextro Aspartic Acid Receptor 2D, N-Methyl-D-Aspartate, Neonatal Pneumonia, Neonatal Respiratory Distress Syndrome, Neuroimaging, Nuclear Magnetic Resonance Imaging, Phenobarbital, Premature Labor, Preschool, Preschool Child, Priority Journal, Protein Conformation, Proximal Interphalangeal Joint, Pyridoxine, Receptors, Respiratory Arrest, Sanger Sequencing, School Child, Single Photon Emission Computed Tomography, Sleep Disordered Breathing, Static Electricity, Stridor, Structure-Activity Relationship, Subglottic Stenosis, Superior Temporal Gyrus, Supramarginal Gyrus, Thiopental, Tonic Seizure, Valproic Acid, Wakefulness, Wechsler Intelligence Scale for Children, Whole Exome Sequencing},
pubstate = {published},
tppubtype = {article}
}

@article{Masiran2018b,
title = {Autism and trichotillomania in an adolescent boy},
author = {R Masiran},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053164449&doi=10.1136%2fbcr-2018-226270&partnerID=40&md5=7eed3f6af717df527dce73838feab571},
doi = {10.1136/bcr-2018-226270},
issn = {1757790X},
year = {2018},
date = {2018-01-01},
journal = {BMJ Case Reports},
volume = {2018},
publisher = {BMJ Publishing Group},
abstract = {An adolescent with autism spectrum disorder and improperly treated attention deficit hyperactivity disorder presented with recurrent hair pulling. Treatment with selective serotonin reuptake inhibitor and stimulant improved these conditions. © © BMJ Publishing Group Limited 2018.},
note = {cited By 0},
keywords = {Adolescent, Alopecia, Anxiety, Article, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Autism, Autism Spectrum Disorders, Behaviour Disorder, Body Mass, Case Report, Central Nervous System Stimulants, Child Behaviour Checklist, Clinical Article, Comorbidity, Complication, Diagnosis, Differential, Differential Diagnosis, Drug Dose Titration, Drug Tolerance, DSM-5, Echolalia, Fluvoxamine, Follow Up, Human, Hyperactivity, Intellectual Impairment, Male, Methylphenidate, Obesity, Occupational Therapy, Perceptual Reasoning Index, Priority Journal, Processing Speed Index, Psychiatric Status Rating Scales, Psychological Rating Scale, Rating Scale, Restlessness, Reward, Serotonin Uptake Inhibitor, Serotonin Uptake Inhibitors, Special Education, Speech Delay, Speech Disorder, Speech Therapy, Trichotillomania, Verbal Comprehension Index, Wechsler Intelligence Scale, Working Memory Index},
pubstate = {published},
tppubtype = {article}
}

@article{Charara2017,
title = {The burden of mental disorders in the eastern mediterranean region, 1990-2013},
author = {R Charara and M Forouzanfar and M Naghavi and M Moradi-Lakeh and A Afshin and T Vos and F Daoud and H Wang and C E Bcheraoui and I Khalil and R R Hamadeh and A Khosravi and V Rahimi-Movaghar and Y Khader and N Al-Hamad and C M Obermeyer and A Rafay and R Asghar and S M Rana and A Shaheen and N M E Abu-Rmeileh and A Husseini and L J Abu-Raddad and T Khoja and Z A A Rayess and F S AlBuhairan and M Hsairi and M A Alomari and R Ali and G Roshandel and A S Terkawi and S Hamidi and A H Refaat and R Westerman and A A Kiadaliri and A S Akanda and S D Ali and U Bacha and A Badawi and S Bazargan-Hejazi and I A D Faghmous and S -M Fereshtehnejad and F Fischer and J B Jonas and B K Defo and A Mehari and S B Omer and F Pourmalek and O A Uthman and A A Mokdad and F T Maalouf and F Abd-Allah and N Akseer and D Arya and R Borschmann and A Brazinova and T S Brugha and F Catala-Lopez and L Degenhardt and A Ferrari and J M Haro and M Horino and J C Hornberger and H Huang and C Kieling and D Kim and Y Kim and A K Knudsen and P B Mitchell and G Patton and R Sagar and M Satpathy and K Savuon and S Seedat and I Shiue and J C Skogen and D J Stein and K M Tabb and H A Whiteford and P Yip and N Yonemoto and C J L Murray and A H Mokdad},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009892168&doi=10.1371%2fjournal.pone.0169575&partnerID=40&md5=471830ec1239e37c6fc4681bed5698f6},
doi = {10.1371/journal.pone.0169575},
issn = {19326203},
year = {2017},
date = {2017-01-01},
journal = {PLoS ONE},
volume = {12},
number = {1},
publisher = {Public Library of Science},
abstract = {The Eastern Mediterranean Region (EMR) is witnessing an increase in chronic disorders, including mental illness. With ongoing unrest, this is expected to rise. This is the first study to quantify the burden of mental disorders in the EMR. We used data from the Global Burden of Disease study (GBD) 2013. DALYs (disability-adjusted life years) allow assessment of both premature mortality (years of life lost-YLLs) and nonfatal outcomes (years lived with disability-YLDs). DALYs are computed by adding YLLs and YLDs for each age-sex-country group. In 2013, mental disorders contributed to 5.6% of the total disease burden in the EMR (1894 DALYS/100,000 population): 2519 DALYS/100,000 (2590/100,000 males, 2426/100,000 females) in high-income countries, 1884 DALYS/100,000 (1618/100,000 males, 2157/100,000 females) in middle-income countries, 1607 DALYS/100,000 (1500/100,000 males, 1717/100,000 females) in low-income countries. Females had a greater proportion of burden due to mental disorders than did males of equivalent ages, except for those under 15 years of age. The highest proportion of DALYs occurred in the 25-49 age group, with a peak in the 35-39 years age group (5344 DALYs/100,000). The burden of mental disorders Burden of Mental Disorders in EMR PLOS ONE in EMR increased from 1726 DALYs/100,000 in 1990 to 1912 DALYs/100,000 in 2013 (10.8% increase). Within the mental disorders group in EMR, depressive disorders accounted for most DALYs, followed by anxiety disorders. Among EMR countries, Palestine had the largest burden of mental disorders. Nearly all EMR countries had a higher mental disorder burden compared to the global level. Our findings call for EMR ministries of health to increase provision of mental health services and to address the stigma of mental illness. Moreover, our results showing the accelerating burden of mental health are alarming as the region is seeing an increased level of instability. Indeed, mental health problems, if not properly addressed, will lead to an increased burden of diseases in the region. © 2017 Charara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.},
note = {cited By 30},
keywords = {80 and Over, Adolescent, Adult, Age, Age Factors, Aged, Anxiety Disorder, Article, Attention Deficit Disorder, Autism, Bipolar Disorder, Children, Conduct Disorder, Depression, Elderly People, Female, Global Health, Groups by Age, Health Status, Highest Income Group, Human, Infant, Intellectual Impairment, Kuwait, Life Expectancy, Major Clinical Study, Male, Mediterranean Region, Mental Disease, Mental Disorders, Mental Health, Mental Health Service, Middle Aged, Middle Income Group, Mortality, Newborn, Palestine, Premature Mortality, Preschool, Preschool Child, Prevalence, Qatar, Quality Adjusted Life Year, Schizophrenia, Sex Difference, Sex Factors, Southern Europe, Time Factor, Time Factors, United Arab Emirates, Young Adult},
pubstate = {published},
tppubtype = {article}
}

@article{Tan2016,
title = {Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders},
author = {M L Tan and J J Ho and K H Teh},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988922340&doi=10.1002%2f14651858.CD009398.pub3&partnerID=40&md5=3460f403b8829b4692a0b6f795f4a2a3},
doi = {10.1002/14651858.CD009398.pub3},
issn = {1469493X},
year = {2016},
date = {2016-01-01},
journal = {Cochrane Database of Systematic Reviews},
volume = {2016},
number = {9},
publisher = {John Wiley and Sons Ltd},
abstract = {Background: About 5% of school children have a specific learning disorder, defined as unexpected failure to acquire adequate abilities in reading, writing or mathematics that is not a result of reduced intellectual ability, inadequate teaching or social deprivation. Of these events, 80% are reading disorders. Polyunsaturated fatty acids (PUFAs), in particular, omega-3 and omega-6 fatty acids, which normally are abundant in the brain and in the retina, are important for learning. Some children with specific learning disorders have been found to be deficient in these PUFAs, and it is argued that supplementation of PUFAs may help these children improve their learning abilities. Objectives: 1. To assess effects on learning outcomes of supplementation of polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.2. To determine whether adverse effects of supplementation of PUFAs are reported in these children. Search methods: In November 2015, we searched CENTRAL, Ovid MEDLINE, Embase, PsycINFO, 10 other databases and two trials registers. We also searched the reference lists of relevant articles. Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs comparing PUFAs with placebo or no treatment in children younger than 18 years with specific learning disabilities, as diagnosed in accordance with the fifth (or earlier) edition of theDiagnostic and Statistical Manual of Mental Disorders (DSM-5), or the 10th (or earlier) revision of the International Classification of Diseases (ICD-10) or equivalent criteria. We included children with coexisting developmental disorders such as attention deficit hyperactivity disorder (ADHD) or autism. Data collection and analysis: Two review authors (MLT and KHT) independently screened the titles and abstracts of articles identified by the search and eliminated all studies that did not meet the inclusion criteria. We contacted study authors to ask for missing information and clarification, when needed. We used the GRADE approach to assess the quality of evidence. Main results: Two small studies involving 116 children, mainly boys between 10 and 18 years of age, met the inclusion criteria. One study was conducted in a school setting, the other at a specialised clinic. Both studies used three months of a combination of omega-3 and omega-6 supplements as the intervention compared with placebo. Although both studies had generally low risk of bias, we judged the risk of reporting bias as unclear in one study, and as high in the other study. In addition, one of the studies was funded by industry and reported active company involvement in the study. None of the studies reported data on the primary outcomes of reading, writing, spelling and mathematics scores, as assessed by standardised tests. Evidence of low quality indicates that supplementation of PUFAs did not increase the risk of gastrointestinal disturbances (risk ratio 1.43, 95% confidence interval 0.25 to 8.15; two studies, 116 children). Investigators reported no other adverse effects. Both studies reported attention deficit hyperactivity disorder (ADHD)-related behaviour outcomes. We were unable to combine the results in a meta-analysis because one study reported findings as a continuous outcome, and the other as a dichotomous outcome. No other secondary outcomes were reported. We excluded one study because it used a cointervention (carnosine), and five other studies because they did not provide a robust diagnosis of a specific learning disorder. We identified one ongoing study and found three studies awaiting classification. Authors' conclusions: Evidence is insufficient to permit any conclusions about the effect of PUFAs on the learning abilities of children with specific learning disorders. Well-designed RCTs with clearly defined populations of children with specific learning disorders who have been diagnosed by standardised diagnostic criteria are needed. © 2016 The Cochrane Collaboration.},
note = {cited By 6},
keywords = {Attention Deficit Disorder, Autism, Carnosine, Children, Diet Supplementation, Drug Effect, Gastrointestinal Symptom, Human, Learning Disorder, Meta Analysis, Outcome Assessment, Placebo, Polyunsaturated Fatty Acid, Priority Journal, Randomized Controlled Trial, Review, Systematic Review},
pubstate = {published},
tppubtype = {article}
}